The following is a summary of “Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

“Bladder cancer that recurs after BCG has historically been very difficult to treat,” said Stephen A. Boorjian, MD, Professor of Urology at the Mayo Clinic, Rochester, US, and principal ...

doxorubicin or pirarubicin), whether immediately after surgery or after 2 weeks' delay, had similar outcomes to those who did not. By contrast, the 35 patients who received intravesical BCG ...

Following surgery to remove the tumor, bladder cancer patients are typically given a live Bacillus Calmette Guerin (BCG) inoculation ... Joost Boormans, Professor of Urology at the Erasmus ...

Bacillus Calmette-Guérin (BCG)–unresponsive non-muscle invasive bladder cancer with carcinoma in situ, according to a news release from CG Oncology, Inc. In a presentation of data given at the 40th ...

Intravesical cretostimogene continues to show durable response for up to 22 months in patients with high-risk BCG-unresponsive ... European Association of Urology (EAU) Congress in Madrid, Spain.

“Constrained BCG supply has improved stewardship of a limited resource but has come at a high cost to our patients,” said Dr. Chad Reichard, Co-Director of Clinical Research, Urology of Indiana.